Niger Archives - TBC repository

Home
/
Projects

Niger

Supporting countries with prioritization of new vaccine introductions (NVI) and portfolio optimization

Support countries with using multi-criteria decision analysis (MCDA) for prioritization of new vaccine introductions (NVI) (including new TB vaccines) and portfolio optimization, embedded in the NIS development process. The project's key questions are: 1. How can we best support countries with NVI including new TB vaccine prioritization regarding access to evidence, tools, technical support? 2. What criteria do countries use when prioritizing NVIs? 3. How to best align NVI prioritization with the NIS development process.

Facing up to reality? What to do if M72/AS01E doses are limited

M72/AS01e

Ongoing

The Ph3 trial for the vaccine candidate M72/AS01E is underway, and, assuming a positive result, could be licensed by 2030. Modelling suggested a large potential impact from introducing M72/AS01E but assumed an unconstrained dose supply. However, at least initially, it is likely that M72/AS01E will be supply-constrained. We estimated the effect of decisions surrounding the allocation of constrained doses on the potential global impact of M72/AS01E

Cost and Cost Effectiveness of Novel Tuberculosis Vaccines in Low-and Middle-income Countries: A Systematic Review of Modelling Studies

hypothetical, M72/AS01e

Ongoing

This review addressed the costs and cost-effectiveness of novel tuberculosis (TB) vaccines compared to the current standard of care (BCG) in various settings and for different age groups in LMICs

Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.

2014

Hypothetical vaccines

Completed

To aid in prioritizing the development of tuberculosis (TB) vaccines most likely to reach the 2050 TB elimination goal, we estimated the impact and cost-effectiveness of a range of vaccine profiles in low- and middle-income countries.

The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study

2023

Hypothetical vaccines

Completed

We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

2023

Hypothetical vaccines

Completed

We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.

The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries

2023

Hypothetical vaccines

Completed

We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.